Quidel Corp, a maker of COVID-19 tests, agreed to buy Ortho Clinical Diagnostics Holdings for about US$6 billion, less than a year since the Carlyle-backed firm went public.
Quidel said on Thursday it would pay Ortho Clinical US$24.68 per share, representing a premium of 24.7% to Ortho Clinical’s last close, in a cash and stock deal and will acquire Ortho’s existing net debt of US$2 billion.
Ortho Clinical makes products for diagnosing diseases and other equipment used for in-vitro diagnostics, a nearly US$80 billion market that serves hospitals and clinics. It also has several COVID-19 tests authorized for emergency use in the United States.
Read more/Source: The Edge Markets
